Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Post-treatment Controllers

  • Asier Sáez-Cirión
  • Laurent Hocqueloux
  • Christine Rouzioux
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_201-1


Post-treatment controllers (PTC) are HIV-infected patients able to maintain a durable control of viremia at undetectable levels after interruption of antiretroviral treatment. Differently from natural HIV “elite” controllers (HIC), post-treatment controllers require therapeutic intervention to first reach undetectable viral loads. Post-treatment controllers still carry infected cells and, thus, are not cured but considered to be in sustained remission of HIV infection. These patients have also been termed “secondary controllers.”


The introduction of combination antiretroviral treatment (cART) as the standard of care for HIV-infected individuals changed the face of the AIDS epidemics. cART has drastically reduced mortality and morbidities of HIV-infected patients (Boyd 2009) and has also proven its value as a prevention tool by decreasing the risk of transmission (Cohen et al. 2011). A few years after cART was implemented, it was hypothesized that the perfectly...


Viral Load Treatment Interruption Viral Reservoir Viral Rebound Viral Blip 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. In: 20th conference on retroviruses and opportunistic infections, Atlanta, 3–6 Mar 2013. Abstract 47.Google Scholar
  2. Ananworanich J, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014;28(7):1015–20.PubMedCrossRefGoogle Scholar
  3. Boufassa F, et al. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014;9(1):e85516.PubMedCentralPubMedCrossRefGoogle Scholar
  4. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4(3):194–9.PubMedCrossRefGoogle Scholar
  5. Buzon MJ, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88(17):10056–65.PubMedCrossRefGoogle Scholar
  6. Cohen MS, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRefGoogle Scholar
  7. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37(3):377–88.PubMedCentralPubMedCrossRefGoogle Scholar
  8. Fiebig EW, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871–9.PubMedCrossRefGoogle Scholar
  9. Goujard C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001–9.PubMedCrossRefGoogle Scholar
  10. Hocqueloux L, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598–601.PubMedCrossRefGoogle Scholar
  11. Hocqueloux L, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68(5):1169–78.PubMedCrossRefGoogle Scholar
  12. Hutter G, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8.PubMedCrossRefGoogle Scholar
  13. Lodi S, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172(16):1252–5.PubMedCrossRefGoogle Scholar
  14. Luzuriaga K, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014. doi:10.1093/infdis/jiu297.Google Scholar
  15. O’Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep. 2012;9(2):101–10.PubMedCentralPubMedCrossRefGoogle Scholar
  16. Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis. 2008;21(1):25–30.PubMedCrossRefGoogle Scholar
  17. Persaud D, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828–35.PubMedCentralPubMedCrossRefGoogle Scholar
  18. Piketty C, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol. 2010;82(11):1819–28.PubMedCrossRefGoogle Scholar
  19. Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407(6803):523–6.PubMedCrossRefGoogle Scholar
  20. Saez-Cirion A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev. 2013;254(1):281–94.PubMedCrossRefGoogle Scholar
  21. Saez-Cirion A, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.PubMedCentralPubMedCrossRefGoogle Scholar
  22. Salgado M, et al. Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology. 2011;8:97.PubMedCentralPubMedCrossRefGoogle Scholar
  23. Steingrover R, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS. 2008;22(13):1583–8.PubMedCrossRefGoogle Scholar
  24. Van Gulck E, et al. Immune and viral correlates of “secondary viral control” after treatment interruption in chronically HIV-1 infected patients. PLoS One. 2012;7(5):e37792.PubMedCentralPubMedCrossRefGoogle Scholar
  25. Whitney JB, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74–7.PubMedGoogle Scholar
  26. Yukl SA, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013;9(5):e1003347.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Asier Sáez-Cirión
    • 1
  • Laurent Hocqueloux
    • 2
  • Christine Rouzioux
    • 3
    • 4
  1. 1.Institut PasteurUnité de Régulation des Infections RétroviralesParisFrance
  2. 2.CHR d’Orléans- La SourceService des Maladies Infectieuses et TropicalesOrléansFrance
  3. 3.Hopital Necker, Laboratoire de VirologieUniversité Paris DescartesParisFrance
  4. 4.Université Paris DescartesParisFrance